MYND Life Sciences Inc. (MYNDF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.51 Million CAD | 57.45% |
| 2022 | -3.56 Million CAD | 18.32% |
| 2021 | -4.36 Million CAD | -7634.21% |
| 2020 | -56.46 Thousand CAD | -2127.46% |
| 2019 | -2535.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -379.27 Thousand CAD | -46.12% |
| 2024 Q2 | -259.56 Thousand CAD | 30.37% |
| 2024 Q1 | -372.76 Thousand CAD | -179.47% |
| 2023 Q4 | 469.03 Thousand CAD | 188.37% |
| 2023 FY | -1.51 Million CAD | 57.45% |
| 2023 Q3 | -530.77 Thousand CAD | 14.06% |
| 2023 Q2 | -617.61 Thousand CAD | 26.34% |
| 2023 Q1 | -838.5 Thousand CAD | -51.66% |
| 2022 Q2 | -859.04 Thousand CAD | 34.47% |
| 2022 Q1 | -1.31 Million CAD | 14.32% |
| 2022 FY | -3.56 Million CAD | 18.32% |
| 2022 Q4 | -552.88 Thousand CAD | 35.11% |
| 2022 Q3 | -851.96 Thousand CAD | 0.82% |
| 2021 Q2 | -778.21 Thousand CAD | 34.63% |
| 2021 Q4 | -1.53 Million CAD | -76.17% |
| 2021 Q3 | -868.47 Thousand CAD | -11.6% |
| 2021 FY | -4.36 Million CAD | -7634.21% |
| 2021 Q1 | -1.19 Million CAD | 0.0% |
| 2020 FY | -56.46 Thousand CAD | -2127.46% |
| 2019 FY | -2535.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.975% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 76.919% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.09% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.865% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.33% |
| Mesoblast Limited | -87.95 Million USD | 98.274% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 16.625% |
| Genus plc | 7.9 Million USD | 119.213% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 86.064% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 59.09% |
| Marizyme, Inc. | -65.34 Million USD | 97.677% |
| ContraFect Corporation | -65.15 Million USD | 97.67% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 82.837% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 68.935% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 12.133% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 47.522% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 81.167% |
| MultiCell Technologies, Inc. | -380.07 USD | -399263.275% |
| Accustem Sciences Inc. | -3.74 Million USD | 59.485% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.064% |
| EV Biologics, Inc. | -1.26 Million USD | -19.787% |
| Q BioMed Inc. | -2.05 Million USD | 26.034% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 59.339% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -140.013% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 36.248% |
| Biomind Labs Inc. | -1.21 Million USD | -24.997% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 85.61% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 80.794% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.968% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 30.047% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -10035.283% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 78.263% |
| IMV Inc. | -36.48 Million USD | 95.84% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 90.437% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 73.908% |
| GB Sciences, Inc. | -1.36 Million USD | -11.47% |
| Alpha Cognition Inc. | -13.77 Million USD | 88.979% |
| HST Global, Inc. | -146.21 Thousand USD | -938.137% |
| CSL Limited | 2.64 Billion USD | 100.057% |
| Halberd Corporation | -79.67 Thousand USD | -1805.04% |
| Enzolytics Inc. | -2.17 Million USD | 30.272% |
| Resverlogix Corp. | -3.61 Million USD | 57.954% |
| Affymax, Inc. | -14.42 Million USD | 89.477% |
| SYBLEU INC | -180.3 Thousand USD | -741.834% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 52.14% |
| argenx SE | -295.05 Million USD | 99.486% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.575% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1648.837% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 61.796% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 49.842% |
| AVAX Technologies, Inc. | -6.41 Million USD | 76.334% |
| Zenith Capital Corp. | -10.59 Million USD | 85.675% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.41% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -6430.677% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 63.389% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2411.325% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.459% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 51.065% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -43.729% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 22.131% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 60.255% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 24.301% |
| BioStem Technologies, Inc. | -8.48 Million USD | 82.107% |
| ONE Bio Corp. | 8.67 Million USD | 117.494% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -243.898% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -13.661% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 13.501% |
| Agentix Corp. | -1.37 Million USD | -10.453% |
| LadRx Corporation | 400.44 Thousand USD | 479.045% |
| Cell Source, Inc. | -5.32 Million USD | 71.475% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -265.328% |
| Regen BioPharma, Inc. | 1.02 Million USD | 248.3% |
| Regen BioPharma, Inc. | 1.02 Million USD | 248.3% |
| NovAccess Global Inc. | -4.76 Million USD | 68.174% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 121.92% |
| Itoco Inc. | -1.86 Million USD | 18.787% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 65.833% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 9.056% |
| Kadimastem Ltd | -3.3 Million USD | 54.107% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -455.175% |
| CytoDyn Inc. | -49.84 Million USD | 96.955% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1820.54% |
| Mobile Lads Corp. | -2.26 Million USD | 32.936% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -565.357% |
| Qrons Inc. | -789.34 Thousand USD | -92.293% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -61.212% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 27.294% |
| Rebus Holdings, Inc. | -1.02 Million USD | -48.81% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 5.883% |
| International Stem Cell Corporation | -131 Thousand USD | -1058.672% |
| Bioxytran, Inc. | -4.28 Million USD | 64.536% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2696.764% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 40.011% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.843% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 28.2% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -94.376% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 52.088% |
| Neutra Corp. | -233.46 Thousand USD | -550.145% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 92.52% |
| PureTech Health plc | -65.69 Million USD | 97.69% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 92.863% |
| IXICO plc | -1.17 Million USD | -28.851% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 84.71% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.343% |
| CSL Limited | 2.64 Billion USD | 100.057% |
| Cellectis S.A. | -103.17 Million USD | 98.529% |